Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients.
circulating tumor DNA
gastric cancer
minimal residual disease
monitoring
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 Mar 2019
21 Mar 2019
Historique:
received:
13
02
2019
revised:
14
03
2019
accepted:
18
03
2019
entrez:
24
3
2019
pubmed:
25
3
2019
medline:
25
3
2019
Statut:
epublish
Résumé
This study was designed to monitor circulating tumor DNA (ctDNA) levels during perioperative chemotherapy in patients with non-metastatic gastric adenocarcinoma. Plasma samples were prospectively collected in patients undergoing perioperative chemotherapy for non-metastatic gastric adenocarcinoma (excluding T1N0) prior to the initiation of perioperative chemotherapy, before and after surgery (NCT02220556). In each patient, mutations retrieved by targeted next-generation sequencing (NGS) on tumor samples were then tracked in circulating cell-free DNA from 4 mL of plasma by droplet digital PCR. Thirty-two patients with a diagnosis of non-metastatic gastric adenocarcinoma were included. A trackable mutation was identified in the tumor in 20 patients, seven of whom experienced relapse during follow-up. ctDNA was detectable in four patients (
Identifiants
pubmed: 30901876
pii: cancers11030396
doi: 10.3390/cancers11030396
pmc: PMC6468548
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : The Institut Curie ICGex NGS platform is funded by the EQUIPEX "investissements d'avenir" program and ANR10-INBS-09-08 from the Agence Nationale de le Recherche. Entrepreneurs and Go, fédération de protection et d'accompagnement des entrepreneurs
ID : x
Références
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
Nat Med. 2008 Sep;14(9):985-90
pubmed: 18670422
Ann Surg Oncol. 2010 Dec;17(12):3077-9
pubmed: 20882416
Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9530-5
pubmed: 21586637
Br J Cancer. 2011 Jun 7;104(12):1840-7
pubmed: 21610705
N Engl J Med. 2013 Mar 28;368(13):1199-209
pubmed: 23484797
Ann Oncol. 2013 Aug;24(8):2057-61
pubmed: 23676420
Sci Transl Med. 2013 Oct 16;5(207):207ps14
pubmed: 24132635
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Br J Cancer. 2015 Jan 20;112(2):352-6
pubmed: 25490524
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
EMBO Mol Med. 2015 Aug;7(8):1034-47
pubmed: 25987569
Sci Transl Med. 2015 Aug 26;7(302):302ra133
pubmed: 26311728
Int J Cancer. 2016 Jun 15;138(12):2974-83
pubmed: 26815009
Cancer Discov. 2016 May;6(5):479-91
pubmed: 26969689
Sci Transl Med. 2016 Jul 6;8(346):346ra92
pubmed: 27384348
Ann Oncol. 2016 Sep;27(suppl 5):v38-v49
pubmed: 27664260
Clin Chem. 2017 Mar;63(3):691-699
pubmed: 28073896
Oncotarget. 2017 Apr 11;8(15):25713-25720
pubmed: 28147337
Eur J Surg Oncol. 2017 May;43(5):949-962
pubmed: 28185687
Nature. 2017 Apr 26;545(7655):446-451
pubmed: 28445469
Eur J Cancer. 2017 Jul;79:15-22
pubmed: 28456090
Ann Oncol. 2017 Aug 1;28(8):1996-2001
pubmed: 28459943
Science. 2018 Feb 23;359(6378):926-930
pubmed: 29348365
Cancer Biomark. 2018;21(4):805-812
pubmed: 29400660
Gut. 2019 Apr;68(4):663-671
pubmed: 29420226
Clin Cancer Res. 2018 Jun 15;24(12):2944-2950
pubmed: 29535126
Oncotarget. 2018 Feb 21;9(19):15144-15156
pubmed: 29599934
World J Gastroenterol. 2018 Jun 7;24(21):2236-2246
pubmed: 29881233
Clin Cancer Res. 2018 Nov 15;24(22):5767-5771
pubmed: 30054279
Front Oncol. 2018 Jul 24;8:275
pubmed: 30087854
Clin Cancer Res. 2018 Dec 15;24(24):6248-6256
pubmed: 30348637
Diagnostics (Basel). 2018 Oct 29;8(4):null
pubmed: 30380690
Nat Rev Genet. 2019 Feb;20(2):71-88
pubmed: 30410101
Cell Mol Life Sci. 2019 May;76(9):1747-1758
pubmed: 30734835